KRAS and neoplasm: Instead, high PDGFRβ expression in the tumor and KRAS mutations emerged as independent prognostic factors for increased risk of death: (HR:1.62, c.i. 1.16–2.24; p = 0.004) and (HR: 1.81, 95% c.i.: 1.20–2.72; p = 0.005), respectively.